Research programme: Alzheimer's disease therapies - Cellzome/Ortho-McNeil Pharmaceutical

Drug Profile

Research programme: Alzheimer's disease therapies - Cellzome/Ortho-McNeil Pharmaceutical

Latest Information Update: 19 Aug 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cellzome; Johnson & Johnson Pharmaceutical Research & Development
  • Class Small molecules
  • Mechanism of Action Amyloid precursor protein secretase modulators; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 12 Mar 2008 Preclinical development is ongoing for Alzheimer's disease
  • 15 Mar 2007 Cellzome receives first milestone payment from Ortho-McNeil Pharmaceutical Inc.
  • 18 Mar 2005 Preclinical trials in Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top